The World Council for Health (WCH) recommends against the use of Remdesivir in people suffering from Covid-19. 

On November 20, 2020, one month after the Food and Drug Administration approved it, the World Health Organization (WHO) issued a statement recommending against the use of Remdesivir, stating:

“WHO has issued a conditional recommendation against the use of Remdesivir in hospitalized patients, regardless of disease severity, as there is currently no evidence that Remdesivir improves survival and other outcomes in these patients.”

Despite this and a continued lack of evidence supporting the use of Remdesivir, doctors in the United States and in the United Kingdom have continued using the drug. Multiple studies have concluded that Remdesivir is not efficacious for treating Covid-19.

Subscription Form | Article Bottom CTA

Subscribe to World Council for Health’s newsletter to get up-to-date information about this

According to Dr Paul Marik, the drug “increases the risk of death and acute kidney injury in hospitalized patients with Covid.” Dr Marik told WCH that “the use of this drug in hospitalized patients is medical malpractice.”

At the same time, there has been a long-term media campaign criticizing the use of Ivermectin and other medicines as treatments for Covid-19, many of which have been shown to be both safe and effective

There are safe, effective, and affordable treatments for Covid-19 that should be used in lieu of the harmful and expensive drug, Remdesivir. WCH also stresses the importance of strengthening one’s immune system in order to be better prepared to fight bacteria and viruses like SARS-CoV-2. 

We are a people-powered platform for world health representing 190+ coalition partners in more than 49 countries.

Creative Commons License
Free Cultural Work

This work is licensed under a Creative Commons Attribution 4.0 International License and is available for republishing and use as a Free Cultural Work.

Leave a Reply

Your email address will not be published. Required fields are marked *